Boltz vs Becton Dickinson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Open-source AI for biomolecular structure prediction. $28M seed from a16z. Pfizer collaboration. Boltz-2 rivals physics methods at 1000x speed. MIT spinout.
About
Boltz was founded as a spinout from MIT with a mission to democratize access to AI-driven biomolecular structure prediction. The company was inspired by the transformative impact of AlphaFold on structural biology and sought to build the next generation of prediction systems that could go beyond protein structure to model the full complexity of biomolecular interactions, including protein-ligand binding, RNA folding, and multi-chain assemblies. By releasing its models as open source, Boltz made frontier-grade structural biology tools available to any researcher with a computer.\n\nBoltz-2, the company's latest model, rivals physics-based molecular dynamics simulations in accuracy while operating at approximately 1,000 times the speed, compressing computational experiments that once required weeks into hours or minutes. This performance profile makes Boltz-2 practical for drug discovery workflows where structural predictions must be generated across millions of candidate molecules. Boltz entered a collaboration with Pfizer, one of the world's largest pharmaceutical companies, to apply its models to drug discovery programs — a validation of both the technology's accuracy and its readiness for industrial-scale deployment.\n\nBoltz raised a $28 million seed round led by Andreessen Horowitz's bio fund, reflecting a16z's conviction that open-source biomolecular AI represents a foundational layer of the next generation of drug discovery infrastructure. The open-source strategy gives Boltz broad academic adoption and a rich pipeline of community feedback that accelerates model improvement. Its MIT lineage, Pfizer partnership, and a16z backing position Boltz as a leading independent AI platform in the computational biology space.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
About
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.